Anti-dengue virus antibodies and uses thereof

• US 9,880,167 B2
• Filed: 10/12/2016
• Issued: 01/30/2018
• Est. Priority Date: 08/07/2012
• Status: Active Grant

• Current Assignee: Massachusetts Institute of Technology
• Original Assignee: Massachusetts Institute of Technology
• Inventors: Sasisekharan, Ram, Robinson, Luke Nathaniel, Tharakaraman, Kannan
• Primary Examiner(s): CHEN, STACY BROWN
• Application Number:
  US15/291,199
• Publication Number:
  US 20170089898A1
• Time in Patent Office: 475 Days
• Field of Search: None
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: C07K 16/10 from RNA viruses
• CPC Class Codes: C07K 16/1081 Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
• CPC Class Codes: C07K 2317/33 Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/565 Complementarity determining region [CDR]
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2317/92 Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
• CPC Class Codes: G01N 2333/185 Flaviviruses or Group B arboviruses, e.g. yellow fever virus, japanese encephalitis, tick-borne encephalitis, dengue
• CPC Class Codes: G01N 2469/10 Detection of antigens from microorganism in sample from host
• CPC Class Codes: G01N 33/56983 Viruses

Abstract

The present invention provides, among other things, antibody agents (e.g., antibodies, and/or antigen-binding fragments thereof) that bind to DV epitopes, as well as compositions containing them and methods of designing, providing, formulating, using, identifying and/or characterizing them. In some embodiments, provided antibody agents show significant binding to a plurality of DV serotypes. In some embodiments, provided antibody agents show significant binding to all four DV serotypes. Such antibody agents are useful, for example, in the prophylaxis, treatment, diagnosis, and/or study of DV.

Claims

1. A method of detecting Dengue virus, the method comprising steps of:

contacting a sample with an antibody agent specific to Dengue virus,

which antibody agent comprises a heavy chain variable region and a light chain variable region, each of which includes complementarity determining regions (CDRs), wherein

the heavy chain variable region comprises CDRs whose amino acid sequences are set forth in SEQ ID NO;

23, SEQ ID NO;

24, and SEQ ID NO;

25;

the light chain variable region comprises CDRs whose amino acid sequences are set forth in SEQ ID NO;

26, SEQ ID NO;

27, and SEQ ID NO;

28; and

detecting binding of the antibody agent to the sample.

2. The method of claim 1, wherein the sample is selected from the group consisting of clinical, environmental, and research samples.

3. The method of claim 1, wherein the sample is or comprises one or more of blood, serum/plasma, peripheral blood mononuclear cells/peripheral blood lymphocytes (PBMC/PBL), sputum, urine, feces, throat swabs, dermal lesion swabs, cerebrospinal fluids, cervical smears, pus samples, food matrices, and tissues from various parts of the body including brain, spleen, and liver.

4. The method of claim 1, wherein the sample is or comprises one or more of soil, water, and flora.